Human Babesiosis Treatment Market to hit new heights worth US$ 1,199 million by 2030: Growth Plus Reports

By GlobeNewswire On Mar 21, 2023

Newark, New Castle, USA, March 21, 2023 (GLOBE NEWSWIRE) — The global human babesiosis treatment market is anticipated to reach US$ 1,199 million by 2030; the high incidence of babesiosis coupled with increasing research and development are primary factors supporting the global human babesiosis treatment market, States Growth Plus Reports.

The global human babesiosis treatment market is driven by the rising prevalence of the disease, increasing awareness about the disease, rising pharmaceutical investments, and an upsurge in research and development activities. The prevalence of babesiosis has been increasing in recent years due to the rise in vector-borne diseases and increasing transmission of the disease through ticks. Additionally, governments and non-governmental organizations (NGOs) initiatives to increase awareness about the disease are projected to drive the human babesiosis treatment market. Moreover, the increasing investment by pharmaceutical companies in developing novel drugs for the treatment of babesiosis is projected to fuel the growth of the global human babesiosis treatment market in the forecast years.

The global human babesiosis treatment market has been analyzed from four perspectives: Drug Class, Mode of Administration, Distribution Channel, and Region.

Request a Sample Copy of the Research Report: https://www.growthplusreports.com/inquiry/request-sample/human-babesiosis-treatment-market/8193

Human Babesiosis Treatment Market Scope

Report Attribute	Details
Market size value in 2021	US$ 780.1 million
Revenue Forecast in 2030	US$ 1199 million
Growth Rate	CAGR of 4.9% from 2022 to 2030
Base year for estimation	2021
Forecast Period	2022-2030
Historical Year	2020
Segments Covered	Drug Class, Mode of Administration, Distribution Channel, and Region
Regional Scope	North America, Europe, Asia Pacific, and the Rest of the World (ROW)

Excerpts from ‘By Drug Class

Based on drug class the global human babesiosis treatment market according to drug class is bifurcated into:

Antiparasitic
Antibiotics

The antiparasitic segment holds the majority of the market share. This is owing to the antiparasitic drug’s efficacy, which reduces the disease’s symptoms. The antiparasitic drug segment is again sub-segmented into atovaquone and quinine. Atovaquone has dominated the segment. Over the years, atovaquone has shown effective results in treating babesiosis. Moreover, due to the drug’s high efficacy in combination with antibiotics such as azithromycin, it is given in the first-line treatment of babesiosis. Atovaquone has many advantages over other treatments, such as its long-acting, fast-acting, and broad-spectrum effects. The antibiotics segment is expected to show high growth in the coming years.

The antibiotics segment is again classified into azithromycin and clindamycin. Among these, azithromycin is highly demanding. For several years, azithromycin has been the preferred antibiotic in treating babesiosis. This drug is highly effective in a wide range of Babesia species. It is effective at treating both acute and chronic infections and is especially useful for cases that are unresponsive to other treatments.

Excerpts from ‘By Mode of Administration’

The global human babesiosis treatment market is divided into two segments based on the mode of administration:

Parenteral
Oral

The oral segment holds the majority of market shares. This is because most medications prescribed to treat babesiosis are available in oral form. Furthermore, oral treatments are simple to use and act fast to relieve symptoms of babesiosis. Additionally, oral drugs have fewer side effects than other kinds of therapy, like intravenous antibiotics.

Excerpts from ‘By Distribution Channel’

Based on distribution channels, the global human babesiosis treatment market is segmented into:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Hospital pharmacy has dominated the market. The hospital pharmacy segment is experiencing growth due to the increasing demand for medications and their need for proper distribution. Hospital pharmacies can provide a more efficient, cost-effective, and convenient way to dispense medications. In addition, hospital pharmacy’s specialized awareness, quality assurance, and safety standards provide an additional benefit to patients.

Excerpts from ‘By Region’

The global human babesiosis treatment market regionally is divided into:

North America
Europe
Asia Pacific
Rest of The World

In 2021, North America held the largest market share. The increasing human babesiosis treatment market in North America is primarily driven by the growth of the region’s population, as the demand for medical care increases. Additionally, the region has seen a rise in the number of medical tourists seeking babesiosis treatments in the area. This trend is further encouraged by the availability of specialized treatments, such as those offered by the Babesia Research Institute. Finally, the region’s governments are investing in modernizing the healthcare infrastructure to make care more accessible, driving the growth of the human babesiosis treatment market.

The market for babesiosis treatment in the Asia Pacific region is expected to grow in the coming years due to several factors. One of the primary drivers of the market is the increasing prevalence of the disease in the region. The presence of vector-borne agents aids the spread of babesiosis. Additionally, the growing awareness regarding the importance of the disease and the need for timely diagnosis and treatment is expected to boost market growth. The rising healthcare expenditure in the region is also projected to support market growth in the forecast years.

Request for Customization – https://www.growthplusreports.com/inquiry/customization/human-babesiosis-treatment-market/8193

Excerpts from ‘Competitive Landscape

Some of the prominent players operating in the global human babesiosis treatment market are:

GlaxoSmithKline plc
Sun Pharmaceuticsl Industries Ltd.
Pliva d.o.o (Teva Pharmaceutical)
Pfizer, Inc.
Camber Pharmaceuticals, Inc.
Galderma S.A.
Abbott Laboratories
Mylan pharmaceutical inc.
Epic Pharma LLC
Otto Pharmaceutical Industries.

Table of Content

INTRODUCTION
1. Market Ecosystem
2. Timeline Under Consideration
  1. Historical Years – 2020
  2. Base Year – 2021
  3. Forecast Years – 2022 to 2030
3. Currency Used in the Report
RESEARCH METHODOLOGY
1. Research Approach
2. Data Collection Methodology
3. Data Sources
  1. Secondary Sources
  2. Primary Sources
4. Market Estimation Approach
  1. Bottom Up
  2. Top Down
5. Market Forecasting Model
6. Limitations and Assumptions
PREMIUM INSIGHTS
1. Current Market Trends
2. Key Players & Competitive Positioning (2021)
MARKET DYNAMICS
1. Drivers
2. Restraints/Challenges
3. Opportunities
GLOBAL HUMAN BABESIOSIS TREATMENT MARKET – ANALYSIS & FORECAST, BY DRUG CLASS
1. Antiparasitic Drugs
  1. Atovaquone
  2. Quinine
2. Antibiotics
  1. Azithromycin
  2. Clindamycin
GLOBAL HUMAN BABESIOSIS TREATMENT MARKET – ANALYSIS & FORECAST, BY MODE OF ADMINISTRATION
1. Oral
2. Intravenous
GLOBAL HUMAN BABESIOSIS TREATMENT MARKET – ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL
1. Hospital Pharmacies
2. Retail Pharmacies
3. Online Pharmacies

TOC Continued..

Buy this Premium Research Report: https://www.growthplusreports.com/checkout-8193

VALUE PROPOSITIONS RELATED TO THE REPORT:

Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
Comprehensive quantitative and qualitative insights at segment and sub-segment level
Covid 19 impact trends and perspective
Granular insights at global/regional/country level
Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
Blanket coverage on competitive landscape
Winning imperatives
Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market

CUSTOMIZATION OPTIONS:

Distributor Landscape Assessment
Pricing Intelligence
Customer Base Assessment
Investment & Initiatives Analysis
‘Business Profile’ of Key Players

Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction

Visit our report store at – https://www.growthplusreports.com/report-store

Browse related reports:

Continuing Medical Education Market by Provider (Universities and Academic Centers), Delivery Mode (Classroom Based Courses, E-Learning Solutions), Application (Oncology, Cardiology) – Global Outlook & Forecast 2023-2031

Clostridium Difficile Infections Treatment Market by Drug (Metronidazole, Vancomycin), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook and Forecast 2023-2031

Bioprocess Technology Market by Product Type (Cell Culture, Flow Cytometry), Application (Biopharmaceuticals, Environmental Management Aid), End User (Hospitals, CROs & CMOs) – Global Outlook & Forecast 2023-2031

Automated Breast Ultrasound Systems Market by Product (Automated Breast Ultrasound System, Automated Breast Volume Scanner), End User (Hospitals, Diagnostics Imaging Laboratories, Clinics) – Global Outlook & Forecast 2023-2031

Attention Deficit Hyperactivity Disorder Market by Drug Class (Stimulant, Non-stimulant), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) – Global Outlook and Forecast 2023-2031

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.

CONTACT: Manan Sethi Director, Market Insights Email: [email protected] 256 Chapman Road STE 105-4, Newark, New Castle - 19702, USA Phone no: +1 888 550 5009 Web: https://www.growthplusreports.com/

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. NewIndiaObserver.com takes no editorial responsibility for the same.